Next Article in Journal
Surgical Oncology: Multidisciplinarity to Improve Cancer Treatment and Outcomes
Next Article in Special Issue
The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
Previous Article in Journal
BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients
Previous Article in Special Issue
The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer
Review

Immunotherapy in the First-Line Setting in Wild-Type NSCLC

1
BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada
2
Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, 2725 Ch Ste-Foy, Québec, QC G1V 4G5, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(6), 4457-4470; https://doi.org/10.3390/curroncol28060378
Received: 16 September 2021 / Revised: 25 October 2021 / Accepted: 29 October 2021 / Published: 3 November 2021
(This article belongs to the Special Issue Current State of Immunotherapy for Lung Cancer)
Treatment algorithms in the treatment of advanced non-small cell lung cancer (NSCLC) continue to evolve as new therapeutics show positive efficacy improvements. This review article summarizes the data for the use of immunotherapy for treatment in first-line stage IV NSCLC, organized by the following four sections: single-agent immunotherapy, immunotherapy and chemotherapy, dual immunotherapy, and dual immunotherapy and chemotherapy. The results are summarized and tabulated. Finally, application of the trial data is illustrated in four clinical scenarios depending on the programmed death-ligand 1 (PD-L1) expression levels. Single checkpoint inhibitors have become an easy and excellent treatment in patients whose tumors have high PD-L1 expression. Adding chemotherapy to immunotherapy benefits our patients. Immunotherapy, with or without chemotherapy, is now the standard of care in the first-line setting in patients without EGFR, ALK, or ROS driver mutations. View Full-Text
Keywords: NSCLC; PD-L1; first-line; immunotherapy; non-small cell lung cancer; squamous; nonsquamous NSCLC; PD-L1; first-line; immunotherapy; non-small cell lung cancer; squamous; nonsquamous
MDPI and ACS Style

Denault, M.-H.; Melosky, B. Immunotherapy in the First-Line Setting in Wild-Type NSCLC. Curr. Oncol. 2021, 28, 4457-4470. https://doi.org/10.3390/curroncol28060378

AMA Style

Denault M-H, Melosky B. Immunotherapy in the First-Line Setting in Wild-Type NSCLC. Current Oncology. 2021; 28(6):4457-4470. https://doi.org/10.3390/curroncol28060378

Chicago/Turabian Style

Denault, Marie-Hélène, and Barbara Melosky. 2021. "Immunotherapy in the First-Line Setting in Wild-Type NSCLC" Current Oncology 28, no. 6: 4457-4470. https://doi.org/10.3390/curroncol28060378

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop